Biogen (NASDAQ:BIIB – Get Free Report)‘s stock had its “outperform” rating restated by analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They presently have a $295.00 price target on the biotechnology company’s stock. Oppenheimer’s price objective suggests a potential upside of 19.25% from the stock’s previous close. Several other equities […]
UBS Group lowered shares of Biogen (NASDAQ:BIIB – Free Report) from a buy rating to a neutral rating in a research note published on Wednesday, MarketBeat.com reports. UBS Group currently has $276.00 price target on the biotechnology company’s stock, down from their previous price target of $311.00. A number of other research firms have also […]
Illinois Municipal Retirement Fund lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 13.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 68,391 shares of the biotechnology company’s stock after acquiring an additional 8,291 shares during the period. Illinois Municipal Retirement […]
MGO One Seven LLC lessened its position in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 17.3% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 1,117 shares of the biotechnology company’s stock after selling 234 shares during the quarter. MGO One Seven LLC’s holdings in Biogen were worth $287,000 at the end […]
Callan Capital LLC lowered its position in Biogen Inc. (NASDAQ:BIIB – Free Report) by 5.7% during the 3rd quarter, Holdings Channel reports. The firm owned 2,489 shares of the biotechnology company’s stock after selling 151 shares during the quarter. Callan Capital LLC’s holdings in Biogen were worth $640,000 at the end of the most recent […]